DB
CNSP icon

Danske Bank’s CNS Pharmaceuticals CNSP Stock Holding History

Danske Bank’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5 Hold
1
– – ﹤0.01% 1089
2026
Q1 		$2 Hold
1
– – ﹤0.01% 1138
2025
Q4 		$5 Hold
1
– – ﹤0.01% 1502
2025
Q3 		$9 Buy
+1
New +$8 ﹤0.01% 1420
2025
Q1 		– Hold
0
– – – 1392
2024
Q4 		– Hold
0
– – – 1463
2024
Q3 		– Hold
0
– – – 1622

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return

Danske Bank's CNSP Position: Q2 2026 in Review

Danske Bank held its CNS Pharmaceuticals (CNSP) position steady in Q2 2026 at 1 share worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Danske Bank first reported a position in CNSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $9 in Q3 2025. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Danske Bank held 1 share of CNS Pharmaceuticals worth $5 as of Q2 2026.
  • Danske Bank left its CNS Pharmaceuticals share count unchanged in Q2 2026.
  • CNS Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1089 holding.
  • Danske Bank first reported a position in CNS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Danske Bank's CNS Pharmaceuticals position peaked at $9 in Q3 2025.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.